Biogen updates Alzheimer’s pipeline plans, shares on Nasdaq in focus
24.06.2026 - 09:45:16 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-24, 09:42.
Biogen Inc. (US09062X1037) remains under scrutiny on the Nasdaq as investors digest its evolving Alzheimer’s and neurology strategy. The biotechnology group sits in the S&P 500 alongside peers Eli Lilly and AbbVie, whose own neuro portfolios shape expectations for Biogen’s next moves.
What recent reports highlight
Biogen has expanded its neurology pipeline with the acquisition of privately held RayThera, a transaction reported on June 19 in connection with a broader biotech news roundup that cited Biogen’s deal-making around gene therapy and central nervous system assets. A Nasdaq market overview noted the RayThera acquisition as part of a weekly review of sector developments.
The same Nasdaq piece placed Biogen’s strategic move in a context that also included an FDA approval for an AbbVie drug and operational measures at smaller biotech names, underlining that Biogen is actively reshaping its portfolio while the wider sector responds to regulatory and funding conditions. This reinforces the perception of Biogen as a large-cap player using bolt-on deals to deepen its neurology focus.
Analyst view on Biogen shares
Morgan Stanley maintained its view on Biogen shares and raised its price target to 224 US dollars in a fresh update cited on June 18, pointing to the risk-reward profile around Alzheimer’s and other neurology programs as a central driver. The analyst action was summarized in a German-language equity overview that referenced the new target level and the unchanged rating. Finanzen100 highlighted the Morgan Stanley move as part of its Biogen stock page.
According to that overview, Biogen’s market capitalization currently stands in the high tens of billions of dollars, a scale that positions it between mid-cap biotech peers and mega-cap pharma groups like Eli Lilly, which also targets Alzheimer’s. The analyst stance underscores that Wall Street continues to value Biogen primarily on its late-stage neurology assets and the commercial trajectory of therapies for Alzheimer’s and related conditions.
More news and data on the Biogen shares
All current headlines, price data and background on Biogen can be found in the dedicated topic area and on the company’s own investor pages.
How Biogen makes its money
Biogen generates most of its revenue from therapies in neurology and neuroimmunology, including treatments for multiple sclerosis and spinal muscular atrophy, and from newer drugs in Alzheimer’s disease and depression. Its portfolio also includes biosimilars that provide more affordable versions of biologic medicines in areas such as immunology and oncology.
Where the Biogen shares trade today
The Biogen shares (US09062X1037) trade on the Nasdaq at around 197 US dollars as of 2026-06-24, 07:30, based on delayed quote data, which implies a market capitalization in the high twenty-billion-dollar range for the S&P 500-listed biotechnology company.
Key data on the Biogen shares
- Company: Biogen Inc.
- ISIN: US09062X1037
- WKN: 789617
- Ticker: BIIB
- Trading venue: Nasdaq
- Price (as of 2026-06-24, 07:30): 197.06 USD
- Market cap: 29.09 billion USD (as of 2026-06-24)
- Sector / industry: Biotechnology / pharmaceuticals
- Index membership: S&P 500
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation to make any financial transaction. All data are based on sources deemed reliable but cannot be guaranteed.
